Company intelligence / Profile preview
Ichor Biologics
New York, New York, United Statesichorbiologics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Ichor Biologics has demonstrated pre-clinical efficacy of its lead antibody-based drugs against lethal hantavirus infections in animal models and received NIH funding to advance development. Published data indicates protection of animals against hantavirus in collaboration with external academic and government partners[3][4].
- Therapeutic areas
- Infectious Diseases
- Modalities
- Monoclonal antibodyAntibody
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
National Institutes of HealthUniversity of Concepción
Beyond the preview
Go deeper on Ichor Biologics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ichor Biologics.